Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | BRD2 | P25440 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21950819 | 1.00 | LMNA (0.38) | LMNACA12CA1CA2CA3 | |
| SCHEMBL9739418 | 0.95 | LMNA (0.34) | LMNACA12CA1CA2CA3 | |
| SCHEMBL12489719 | 0.71 | LMNA (0.44) | LMNACA12CA1CA2CA3 | |
| SCHEMBL19407089 | 0.69 | LMNA (0.43) | LMNACA12CA1CA2CA3 | |
| SCHEMBL10581989 | 0.69 | — | — | |
| SCHEMBL20900421 | 0.68 | LMNA (0.42) | LMNACA12CA1CA2CA3 | |
| SCHEMBL19866030 | 0.67 | LMNA (0.45) | LMNACA12CA1CA2CA3 | |
| SCHEMBL12548433 | 0.67 | LMNA (0.53) | LMNACA12CA1CA2CA3 | |
| SCHEMBL24568172 | 0.66 | LMNA (0.47) | LMNACA12CA1CA2CA3 | |
| SCHEMBL12156957 | 0.66 | LMNA (0.47) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130317013-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | BILLOT XAVIER (CA) | 2013-11-28 | — | — | US | disclosed |
| EP-1513589-B1 | 1,5-DISUBSTITUTED PYRROLID-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF EYE DISEASES SUCH AS GLAUCOMA | MERCK FROSST CANADA LTD (CA) | 2010-11-10 | — | — | EP | disclosed |
| US-20090258918-A1 | EP4 receptor agonist, compositions and methods thereof | BILLOT XAVIER | 2009-10-15 | — | — | US | disclosed |
| US-20050239872-A1 | 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma | MERCK FROSST CANADA LTD. (CA) | 2005-10-27 | — | — | US | disclosed |
| EP-1453503-A4 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | MERCK & CO INC (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1513589-A1 | 1,5-DISUBSTITUTED PYRROLID-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF EYE DISEASES SUCH AS GLAUCOMA | MERCK FROSST CANADA INC. (CA) | 2005-03-16 | — | — | EP | disclosed |
| US-20040204590-A1 | Ep4 receptor agonist, compositions and methods thereof | MERCK FROSST CANADA LTD. (CA) | 2004-10-14 | — | — | US | disclosed |
| EP-1453503-A2 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | Merck & Co., Inc. (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2003103772-A1 | 1,5-DISTRIBUTED PYRROLID-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TEATMENT OF EYE DISEASES SUCH AS GLAUCOMA | MERCK FROSST CANADA & CO. (CA) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003047417-A2 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | MERCK & CO., INC. (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239872-A1 | 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the teatment of eye diseases such as glaucoma | PTGER1, PTGER4, PTGER2 | LMNA 3587/4885CA12 4821/4885CA1 4853/4885 |
| US-20040204590-A1 | Ep4 receptor agonist, compositions and methods thereof | PTGER4, PTGER1, PTGER3 | LMNA 2677/4885CA12 4362/4885CA1 4065/4885 |
| US-20090258918-A1 | EP4 receptor agonist, compositions and methods thereof | PTGER4, PTGER1, PTGER3 | LMNA 2379/4885CA12 4491/4885CA1 4733/4885 |
| US-20130317013-A1 | EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF | PTGER4, PTGER1, PTGER3 | LMNA 2379/4885CA12 4491/4885CA1 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.